Loading
Loading
Product image is a representation โ actual packaging and label may vary.
Nasal Sprays ยท 10ml
๐ Pre-order โ ships from 31 August 2026
This product is pre-order only right now. Your order will be dispatched once stock arrives on 31 August 2026.
$106
AUD ยท 1 pack
Flat rate ยท ships with your order
Melanotan-2 is a synthetic cyclic analog of alpha-MSH studied in preclinical and clinical research for its melanocortin receptor activity. Research has examined its potential to stimulate melanin production, reduce UV-induced skin damage, and modulate appetite and sexual function pathways through MC3R/MC4R activation. Studies have also explored skin photoprotection and partial defence against UV-induced skin damage.
Chemical Properties
Research Use Only โ Disclaimer
These consumable supplies are intended solely for use in research and laboratory settings. All items are sterile and individually packaged for professional handling. BAC water is for peptide reconstitution purposes only and is not intended for injection without appropriate professional supervision. Not for human or animal consumption in any form.
Melanotan II
MT-II
Melanotan II (MT-2) is a cyclic lactam heptapeptide analog of alpha-melanocyte-stimulating hormone (ฮฑ-MSH), developed at the University of Arizona in the early 1980s as part of research into melanoma prevention through enhanced natural melanogenesis. Its cyclic conformation confers broader melanocortin receptor subtype activity and higher potency compared to the linear Melanotan I.
MT-2 is a non-selective melanocortin receptor agonist with activity at MC1R, MC3R, MC4R, and MC5R. MC1R stimulation on melanocytes drives eumelanin (dark brown pigment) production via cAMP elevation and subsequent PKA activation, increasing melanin synthesis without UV exposure. MC4R activation in the hypothalamus produces appetite suppression and activates pathways associated with sexual arousal. MC3R involvement may contribute to energy homeostasis effects.
Originally studied as a photoprotective pigmentation agent, MT-2 research expanded to sexual function (leading to the discovery of bremelanotide/PT-141), appetite regulation, and inflammatory modulation. The compound's non-selectivity means research must account for simultaneous activities at multiple receptor subtypes. MT-2 is not approved by any regulatory authority for therapeutic use; all data is from preclinical or observational contexts.
Key References
For research reference only. All information pertains to preclinical or published human trial data. Not intended as medical advice. This product is for research use only.
